Nano Carrier IR report 2017

5/12

pecial Talk ▶SClinical study is quite important but therefore difficult.For this reason, the future lies in overcoming this difficulty.NakatomiDr. SaijoNakatomiDr. SaijoNakatomiDr. Saijoso in 2017 it is just now celebrating its 15th anniversary.You also have made great contributions over many years in promoting and raising social recognition of clinical oncology.It certainly was not a smooth journey. Until JSMO was found-ed, treatment for the cancer patient in Japan was primarily surgery, and the level of awareness of treating cancer with medicine was far lower compared to today. Understanding of how to conduct clinical trials was also inadequate and the concept of clinical oncology was unclear. There were not even courses related to clinical oncology in faculties of medicine, and our rst mission was to make society aware of clinical oncology.In addition to your activities for JSMO, you have naturally been involved in many clinical development projects. There are so many questions I would like to ask you from your perspective as someone involved in that clinical development, so I am really looking forward to our discussion today.I am deeply honored to be here.For the sake of the patients suffering from cancer, the Japanese Society of Medical Oncology (JSMO) is aiming for the development of more advanced treatments and conducts initiatives such as promoting clinical trials and training experts. This time, we welcome the Special Advisor of JSMO, Dr. Nagahiro Saijo, who has been working tireless-ly to establish an environment in Japan in which oncologists can be active, and has also served actively as an advisor to clinical development companies. He and our President, Dr. Nakatomi, discussed the difficulty and importance of clinical development, and a vision of the future of cancer treatments without side effects.Dr. Saijo, JSMO was founded due to your great efforts, and you served as its rst President. How many years is it now since JSMO was founded?The JSMO was established as a voluntary organization in 2002 by its predecessor, the Study Group of the Japanese Society of Medical Oncology that had been founded in 1993,5Nagahiro Saijo Contribution to promoting and raising social recognition of clinical oncologyGraduated in 1968 from the Faculty of Medicine, Osaka University. In 1972, after completion of training at the 3rd Department of Internal Medicine, Osaka University School of Medicine, he became a physician at the National Cancer Center (NCC) Outpatient Clinic. He was promoted to Medical Director of the NCC Hospital Wards in 1978, he became Director of the Pharmacology Division of NCC Research Institute in 1989, Director of the Internal Medicine Division in 1997, and the Vice-Director of the NCC Hospital East in 2004. In 2009, he became Professor of the Department of Medical Oncology, Kinki University Faculty of Medicine, and he has held his current position since April 2012. Previously, he was a Board of Directors of the American Society of Clinical Oncology (ASCO), President of International Association for the Study of Lung Cancer (IASLC), a member of the international representative and membership committee of European Society for Medical Oncology (ESMO), and has been a director of the Japanese Cancer Association, the Japan Society of Clinical Oncology, the Japan Lung Cancer Society, and the Japanese Association for Molecular Target Therapy of Cancer. He founded the Japanese Society of Medical Oncology and served as its first President from 2002-2009.Nagahiro Saijo, M.D., Ph.D.Japanese Society of Medical OncologySpecial Advisor, HeadquartersIchiro NakatomiNanoCarrier Co., LtdPresident & CEO